Literature DB >> 24280765

Current investigation and management of patients with syncope: results of the European Heart Rhythm Association survey.

Nikolaos Dagres1, Maria Grazia Bongiorni, Dan Dobreanu, Antonio Madrid, Jesper Hastrup Svendsen, Carina Blomström-Lundqvist.   

Abstract

The aim of this European Heart Rhythm Association (EHRA) survey was to provide an insight into the current practice of work-up and management of patients with syncope among members of the EHRA electrophysiology research network. Responses were received from 43 centres. The majority of respondents (74%) had no specific syncope unit and only 42% used a standardized assessment protocol or algorithm. Hospitalization rates varied from 10% to 25% (56% of the centres) to >50% (21% of the centres). The leading reasons for hospitalization were features suggesting arrhythmogenic syncope (85% of respondents), injury (80%), structural heart disease (73%), significant comorbidities (54%), and older age (41%). Most widely applied tests were electrocardiogram (ECG), echocardiography, and Holter monitoring followed by carotid sinus massage and neurological evaluation. An exercise test, tilt table test, electrophysiological study, and implantation of a loop recorder were performed only if there was a specific indication. The use of a tilt table test varied widely: 44% of respondents almost always performed it when neurally mediated syncope was suspected, whereas 37% did not perform it when there was a strong evidence for neurally mediated syncope. Physical manoeuvres were the most widely (93%) applied standard treatment for this syncope form. The results of this survey suggest that there are significant differences in the management of patients with syncope across Europe, specifically with respect to hospitalization rates and indications for tilt table testing in neurally mediated syncope. The majority of centres reported using ECG, echocardiography, and Holter monitoring as their main diagnostic tools in patients with syncope, whereas a smaller proportion of centres applied specific assessment algorithms. Physical manoeuvres were almost uniformely reported as the standard treatment for neurally mediated syncope.

Entities:  

Keywords:  EHRA survey; EP wire; Syncope; Syncope unit; Tilt test

Mesh:

Year:  2013        PMID: 24280765     DOI: 10.1093/europace/eut354

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  6 in total

Review 1.  New insight on the molecular mechanisms of high-density lipoprotein cellular interactions.

Authors:  L O Martinez; S Jacquet; F Tercé; X Collet; B Perret; R Barbaras
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

Review 2.  [Syncope : epidemiology, definition, classification, pathophysiology and prognosis].

Authors:  C-H Heeger; A Rillig; F Ouyang; K-H Kuck; R R Tilz
Journal:  Herz       Date:  2014-06       Impact factor: 1.443

3.  [Syncope and dizziness].

Authors:  R R Tilz; K-H Kuck
Journal:  Herz       Date:  2014-06       Impact factor: 1.443

4.  Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate.

Authors:  A Hrzenjak; H Reicher; A Wintersperger; B Steinecker-Frohnwieser; P Sedlmayr; H Schmidt; T Nakamura; E Malle; W Sattler
Journal:  Cell Mol Life Sci       Date:  2004-06       Impact factor: 9.261

Review 5.  Clinical evaluation and risk stratification in patients with syncope.

Authors:  T Koenig; D Duncker; S Hohmann; C Schroeder; H Oswald; C Veltmann
Journal:  Herz       Date:  2014-06       Impact factor: 1.443

6.  Confirmation of Cause of Death Via Comprehensive Autopsy and Whole Exome Molecular Sequencing in People With Epilepsy and Sudden Unexpected Death.

Authors:  C Anwar A Chahal; David J Tester; Ahmed U Fayyaz; Keerthi Jaliparthy; Nadeem A Khan; Dongmei Lu; Mariha Khan; Aradhana Sahoo; Aiswarya Rajendran; Jennifer A Knight; Michael A Simpson; Elijah R Behr; Elson L So; Erik K St Louis; R Ross Reichard; William D Edwards; Michael J Ackerman; Virend K Somers
Journal:  J Am Heart Assoc       Date:  2021-11-24       Impact factor: 6.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.